Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 1

Status

Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Colorectal Neoplasms 38Pancreatic Neoplasms 16Colonic Neoplasms 12Rectal Neoplasms 11Stomach Neoplasms 9Neoplasms 9Neuroblastoma 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Neoplasm Metastasis 7Glioblastoma 7Sarcoma, Ewing 6Gastrointestinal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Glioma 5Sarcoma 4Brain Neoplasms 4Medulloblastoma 3Intestinal Neoplasms 3Gliosarcoma 3Gastrointestinal Diseases 3Esophageal Neoplasms 3Digestive System Neoplasms 3Digestive System Diseases 3Astrocytoma 3Advanced Solid Tumors 3Recurrence 2Rectal Diseases 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

Injections 7pembrolizumab 5Paclitaxel 5Bevacizumab 5Leucovorin 4Fluorouracil 4Carboplatin 4trifluridine tipiracil drug combination 3Pemetrexed 3Oxaliplatin 3Irinotecan 3Docetaxel 3Capecitabine 3toripalimab 2tislelizumab 2fludarabine 2Nivolumab 2Gemcitabine 2Fulvestrant 2Cisplatin 2BMS-753493 2130-nm albumin-bound paclitaxel 2urelumab 1ulixertinib 1palbociclib 1mogamulizumab 1lenvatinib 1fluzoparib 1duvelisib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumors × Irinotecan × Clear all
NCT05083481 2026-05-05

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Astellas Pharma Inc

Phase 1/2 Active not recruiting
226 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05824455 2024-09-05

A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors

Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.

Phase 1/2 Terminated
4 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05865925 2024-04-25

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Luye Pharma Group Ltd.

Phase 1/2 Unknown
78 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡